What Published Studies and FDA Labeling Reveal About Tysabri and PML Risk
Latest update (2026-07)
Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]
From General Health Information to Legal Action: The Tysabri Context
If you or a loved one developed progressive multifocal leukoencephalopathy (PML) after taking Tysabri, you are likely seeking clear, evidence-based information about this rare brain infection and its connection to the drug. Decades of pharmacovigilance and peer-reviewed research have established a well-documented link between Tysabri use and JC virus reactivation, which can lead to PML. This page reviews the key published reports and FDA labeling context to help you understand the known risks and clinical monitoring recommendations.
Medical Evidence and Risk Factors for Tysabri-Associated PML
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for moderate-to-severe active Crohn’s disease in adults. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Michigan who have developed PML after Tysabri treatment, understanding the medical evidence and legal time limits is critical. The FDA-approved prescribing information for Tysabri includes a Boxed Warning stating that the drug increases the risk of PML, an infection that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors have been identified: the presence of anti-JCV antibodies in the patient’s blood, longer treatment duration (especially beyond two years), and prior use of immunosuppressant medications (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be weighed against expected benefits when initiating or continuing therapy. PML typically presents with subacute neurological deficits. Common early symptoms include progressive weakness on one side of the body, clumsiness, visual disturbances, changes in personality or cognition, and speech difficulties. As the infection spreads in the brain’s white matter, patients may develop seizures, severe disability, and eventually death. Diagnosis relies on brain MRI showing characteristic lesions and detection of JC virus DNA in cerebrospinal fluid via polymerase chain reaction. The clinical course is often rapid, with significant deterioration occurring over weeks to months.
Mechanism of Action and Adverse Event Data
The mechanistic link between Tysabri and PML involves the drug’s mode of action. Tysabri is a monoclonal antibody that binds to alpha-4 integrins on immune cells, preventing their migration from the bloodstream into the brain. This reduces inflammatory damage in multiple sclerosis but also impairs normal immune surveillance against JC virus. In patients who harbor latent JC virus, the loss of immune control allows the virus to reactivate and infect oligodendrocytes, leading to demyelination and the characteristic lesions of PML. Adverse event data from the FDA Adverse Event Reporting System (FAERS) show that among Tysabri-treated patients, the most frequently reported events include fatigue, multiple sclerosis relapse, headache, gait disturbance, and balance disorder (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these are not specific to PML, they underscore the neurological burden in this population. PML itself is a relatively rare but devastating outcome. For patients in Michigan who have been harmed by Tysabri-associated PML, legal considerations include the statute of limitations.
Michigan Statute of Limitations for Tysabri PML Claims
In Michigan, the statute of limitations for personal injury claims is generally three years from the date of injury or from when the injury was discovered, or should have been discovered, through reasonable diligence. For medical malpractice claims, the time limit is typically two years from the date of the alleged malpractice or from when the injury was discovered, with a maximum of six years from the date of the act. Because PML may not be diagnosed immediately after symptom onset, the discovery rule can be critical. The timeline between Tysabri exposure and documented harm varies; PML risk increases with treatment duration, especially beyond two years, but cases have been reported after shorter exposure. Adequacy of warnings is a central issue in potential litigation. The Tysabri label includes a Boxed Warning and a Risk Evaluation and Mitigation Strategy (REMS) called the TOUCH Prescribing Program, which requires prescribers and patients to be educated about PML risk. However, questions may arise about whether patients were adequately informed about the specific risk factors, the severity of PML, and the need for prompt evaluation of new symptoms. If a patient developed PML and the warning was insufficient or not properly communicated, this could form the basis of a failure-to-warn claim. Patients or their families should consult with an attorney experienced in pharmaceutical litigation to evaluate the specific facts of their case, including the date of diagnosis, the duration of Tysabri use, and whether the treating physician followed the TOUCH program requirements. The attorney can determine the applicable statute of limitations and ensure that any legal action is filed within the required timeframe.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Community Resource & Benefit Desk
Request archival records or inquire about member-exclusive transition and benefit programs.
Frequently Asked Questions
What is the statute of limitations for Tysabri PML claims in Michigan?
In Michigan, the statute of limitations for personal injury claims is generally three years from the date of injury or discovery. For medical malpractice, it is typically two years from the date of the alleged malpractice or discovery, with a maximum of six years from the act. Because PML may not be diagnosed immediately, the discovery rule can extend the deadline. Consult an attorney promptly.
What are the risk factors for developing PML from Tysabri?
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.